Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.45 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | RARB | P10826 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MITF | O75030 | 1/20 | 0.41 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.41 |
| ▸ | LPL | P06858 | 1/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL493764 | 0.94 | ALDH1A1 (0.50) | ALDH1A1ALDH3A1ALDH1A3HPGDSMN1; SMN2 | |
| SCHEMBL416529 | 0.88 | RARB (0.56) | ALDH1A1HPGDSMN1; SMN2LMNAMAPT | |
| SCHEMBL16572248 | 0.86 | RARB (0.57) | ALDH1A1LMNAMAPTTHRBRARB | |
| SCHEMBL4716336 | 0.86 | RARB (0.57) | ALDH1A1LMNAMAPTTHRBRARB | |
| SCHEMBL11887470 | 0.85 | ALDH1A1 (0.46) | ALDH1A1ALDH3A1ALDH1A3MCL1HPGD | |
| SCHEMBL17311349 | 0.85 | CYP2A6 (0.48) | ALDH1A1ALDH3A1ALDH1A3MCL1HPGD | |
| SCHEMBL13617779 | 0.85 | RARB (0.58) | ALDH1A1LMNAMAPTTHRBRARB | |
| SCHEMBL13618274 | 0.85 | RARB (0.58) | ALDH1A1LMNAMAPTTHRBRARB | |
| SCHEMBL2121124 | 0.83 | ALDH1A1 (0.61) | ALDH1A1ALDH3A1ALDH1A3HPGDSMN1; SMN2 | |
| SCHEMBL6142777 | 0.82 | ALDH1A1 (0.53) | ALDH1A1ALDH3A1ALDH1A3HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739270-B2 | Polymerizable compound as well as liquid crystal composition and liquid crystal display device each including polymerizable compound | DIC CORPORATION (JP) | 2023-08-29 | — | — | US | disclosed |
| US-20180187079-A1 | COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE USING THE SAME | DIC CORPORATION (JP) | 2018-07-05 | — | — | US | disclosed |
| US-8580146-B2 | Liquid crystal compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-11-12 | — | — | US | disclosed |
| US-8580146-B2 | Liquid crystal compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-11-12 | — | — | US | disclosed |
| US-8580146-B2 | Liquid crystal compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-11-12 | — | — | US | disclosed |
| EP-2544702-A1 | BRIDGED LIPOGLYCOPEPTIDES THAT POTENTIATE THE ACTIVITY OF BETA-LACTAM ANTIBACTERIALS | Merck Sharp & Dohme Corp. (US) | 2013-01-16 | — | — | EP | disclosed |
| US-20120193577-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2012-08-02 | — | — | US | disclosed |
| US-20120193577-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2012-08-02 | — | — | US | disclosed |
| US-20120193577-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2012-08-02 | — | — | US | disclosed |
| EP-0946478-B1 | PROCESS FOR THE SOLID PHASE SYNTHESIS OF ALDEHYDES, KETONES AND HYDROXAMIC ACID COMPOUNDS | AVENTIS PHARMA INC (US) | 2007-02-14 | — | — | EP | disclosed |
| US-6710208-B2 | REACTING AN N-ALKYLATED POLYMERIC HYDROXAMIC ACID RESIN WITH AN ORGANOMETALLIC REAGENT TO LIBERATE THE KETONE | AVENTIS PHARMACEUTICALS INC. | 2004-03-23 | — | — | US | disclosed |
| EP-1359136-A2 | Polymeric resin compounds and their preparation | Aventis Pharmaceuticals Products Inc. (US) | 2003-11-05 | — | — | EP | disclosed |
| US-20020183558-A1 | Process for the solid phase synthesis of aldehyde, ketone, oxime, amine, hydroxamic acid and alpha, beta-unsaturated carboxylic acid and aldehyde compounds | AVENTIS PHARMACEUTICALS INC. | 2002-12-05 | — | — | US | disclosed |
| EP-1089958-A4 | PROCESS FOR THE SOLID PHASE SYNTHESIS OF ALDEHYDE, KETONE, OXIME, AMINE, HYDROXAMIC ACID AND ALPHA,BETA-UNSATURATED CARBOXYLIC ACID AND ALDEHYDE COMPOUNDS | AVENTIS PHARM PROD INC (US) | 2002-10-09 | — | — | EP | disclosed |
| US-6392010-B1 | FLUOROPHENYL HYDROXYLAMINE RESIN | AVENTIS PHARMACEUTICALS INC. | 2002-05-21 | — | — | US | disclosed |
| EP-1089958-A2 | PROCESS FOR THE SOLID PHASE SYNTHESIS OF ALDEHYDE, KETONE, OXIME, AMINE, HYDROXAMIC ACID AND ALPHA,BETA-UNSATURATED CARBOXYLIC ACID AND ALDEHYDE COMPOUNDS | Aventis Pharmaceuticals Products Inc. (US) | 2001-04-11 | — | — | EP | disclosed |
| US-6133409-A | REACTING A SOLID SUPPORT-BOUND N-ALKYLATED HYDROXAMIC ACID WITH A CARBON-NITROGEN CLEAVING ORGANOMETALLIC COMPUND TO LIBERATE THE PRODUCT KETONE | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-10-17 | — | — | US | disclosed |
| WO-1999067192-A2 | PROCESS FOR THE SOLID PHASE SYNTHESIS OF ALDEHYDE, KETONE, OXIME, AMINE, HYDROXAMIC ACID AND α,β-UNSATURATED CARBOXYLIC ACID AND ALDEHYDE COMPOUNDS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-12-29 | — | — | WO | disclosed |
| EP-0946478-A1 | PROCESS FOR THE SOLID PHASE SYNTHESIS OF ALDEHYDES, KETONES, OXIMES, AMINES AND HYDROXAMIC ACID COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998029376-A1 | PROCESS FOR THE SOLID PHASE SYNTHESIS OF ALDEHYDES, KETONES, OXIMES, AMINES AND HYDROXAMIC ACID COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739270-B2 | Polymerizable compound as well as liquid crystal composition and liquid crystal display device each including polymerizable compound | OCIAD2, PKN2, SKP1 | ALDH1A1 3448/4885ALDH3A1 3537/4885ALDH1A3 4286/4885 |
| US-20120193577-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | KIF23, MARK3, CCND3 | ALDH1A1 4082/4885ALDH3A1 2493/4885ALDH1A3 2510/4885 |
| US-20020183558-A1 | Process for the solid phase synthesis of aldehyde, ketone, oxime, amine, hydroxamic acid and alpha, beta-unsaturated carboxylic acid and aldehyde compounds | OGDH, OXGR1, ALDH7A1 | ALDH1A1 19/4885ALDH3A1 27/4885ALDH1A3 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.